Montana Clinical Trials Report — May 2026

For Montanans considering participation in clinical research, May 2026 brings a unique set of opportunities and deadlines. While the state continues to host a robust research environment, a handful of trials are nearing their enrollment close dates, creating a sense of urgency for potential participants. Specifically, 8 clinical trials are scheduled to conclude recruitment within the next 90 days. This includes a valuable opportunity for healthy volunteers, as 1 of these rapidly closing studies is actively seeking individuals without specific health conditions.

Patients managing certain health conditions also have limited time to join research before these studies close. Conditions with trials nearing their end include:

• Castration-resistant prostate carcinoma
• Chronic granulomatous disease (CGD)
• COPD
• Delivery, obstetric
• Depression
• Maternal health
• Mental health
• Mental health services
• Metastatic malignant neoplasm in the bone
• Metastatic prostate carcinoma

Individuals interested in these areas are encouraged to explore their options promptly to avoid missing out on these research opportunities.

A Major New Initiative in Butte: Addressing Overweight and Obesity

This month, Montana welcomes a significant new clinical trial, particularly for those interested in weight management. The pharmaceutical giant Pfizer has launched a notable Phase 2 study, NCT07575932, titled "A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)." This trial is being conducted to understand the safety and effectiveness of two investigational drugs, PF-08653945 and PF-08653944, both when administered alone and in combination, for weight loss. The effects will be compared against a placebo, which is an inactive substance containing no active drug ingredients.

This substantial study aims to enroll a total of 872 participants globally, with a site now open in Butte, Montana. The focus on overweight and obesity addresses a widespread health concern, and the involvement of a major sponsor like Pfizer underscores the importance and potential impact of this research. This trial is specifically designed for adults and includes older adults among its eligible participants.

The conditions targeted by this new trial are broadly defined, reflecting the multifaceted nature of weight-related health challenges:

• Body weight
• Nutrition disorders
• Nutritional and metabolic diseases
• Obesity
• Overnutrition
• Overweight
• Overweight and/or obesity
• Overweight or obesity

This drug trial represents a significant opportunity for residents in and around Butte to contribute to the development of new treatments for these conditions.

Montana's Dynamic Research Landscape

Montana's clinical research environment remains active, with a total of 230 clinical trials currently recruiting across the state. These studies are spread across 18 cities and involve 119 research sites, indicating a broad geographic distribution and accessibility for participants throughout Montana. From major urban centers to smaller communities, opportunities to engage in cutting-edge medical research are available.

While the overall number of recruiting trials is substantial, this month saw a slower pace for new trial openings. Only 1 new trial launched in May 2026, a decrease compared to the 5 new trials that opened in April 2026 and the 2 in March 2026. Despite this dip in new studies, the presence of a significant Phase 2 trial from Pfizer ensures that the quality and potential impact of new research remain high.

Opportunities for Healthy Volunteers

For individuals who do not have a specific medical condition but are interested in contributing to medical science, opportunities exist within Montana's clinical trial landscape. While the single new trial this month does not accept healthy volunteers, there are still 23 trials statewide that are actively recruiting healthy participants. This provides numerous avenues for individuals to contribute to research that helps establish baseline data, test new diagnostic tools, or evaluate the safety of interventions in a healthy population.

It is particularly important to note the 1 trial accepting healthy volunteers that is closing within the next 90 days. This limited-time opportunity means that interested individuals should inquire quickly to secure a spot before enrollment concludes.

Geographic Reach and Participant Demographics

Montana's commitment to clinical research is evident in its widespread availability. With trials recruiting in 18 cities and at 119 sites, residents across the state have potential access to studies. The new Pfizer trial for overweight and obesity, specifically located in Butte, highlights how important research is distributed beyond the largest metropolitan areas, making participation more convenient for many.

Regarding participant demographics, the new Pfizer trial is inclusive of older adults, ensuring that this important population group has the chance to participate in research that could directly benefit them. This month's new trial does not have specific eligibility criteria limited to children, females only, or males only, broadening its potential reach within the adult population.

As we look ahead, Montana's research community will continue to focus on advancing medical knowledge and improving patient care. The ongoing recruitment for the 230 active trials, including the significant new Pfizer study, ensures that the state remains a vital hub for clinical innovation.